Cargando…

Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers

Asymptomatic and pauci-symptomatic cases contribute to underestimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Moreover, we have few studies available on the longitudinal follow-up of SARS-CoV-2 antibodies after natural infection. We tested staff me...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynen, Pascale, Grégoire, Céline, Gofflot, Stéphanie, Seidel, Laurence, Maes, Nathalie, Vranken, Laura, Delcour, Sandra, Moutschen, Michel, Hayette, Marie-Pierre, Kolh, Philippe, Melin, Pierrette, Beguin, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948456/
https://www.ncbi.nlm.nih.gov/pubmed/35338237
http://dx.doi.org/10.1038/s41598-022-09215-8
_version_ 1784674663442415616
author Huynen, Pascale
Grégoire, Céline
Gofflot, Stéphanie
Seidel, Laurence
Maes, Nathalie
Vranken, Laura
Delcour, Sandra
Moutschen, Michel
Hayette, Marie-Pierre
Kolh, Philippe
Melin, Pierrette
Beguin, Yves
author_facet Huynen, Pascale
Grégoire, Céline
Gofflot, Stéphanie
Seidel, Laurence
Maes, Nathalie
Vranken, Laura
Delcour, Sandra
Moutschen, Michel
Hayette, Marie-Pierre
Kolh, Philippe
Melin, Pierrette
Beguin, Yves
author_sort Huynen, Pascale
collection PubMed
description Asymptomatic and pauci-symptomatic cases contribute to underestimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Moreover, we have few studies available on the longitudinal follow-up of SARS-CoV-2 antibodies after natural infection. We tested staff members of a Belgian tertiary academic hospital for SARS-CoV-2 IgG, IgM, and IgA antibodies. We analyzed the evolution of IgM and IgG after 6 weeks, and the persistence of IgG after 3 and 10 months. At the first evaluation, 409/3776 (10.8%) participants had a positive SARS-CoV-2 serology. Among initially seropositive participants who completed phases 2 and 3, IgM were still detected after 6 weeks in 53.1% and IgG persisted at 12 weeks in 82.0% (97.5% of those with more than borderline titers). IgG levels were higher and increased over time in symptomatic but were lower and stable in asymptomatic participants. After 10 months, 88.5% of participants had sustained IgG levels (97.0% of those with more than borderline titers).
format Online
Article
Text
id pubmed-8948456
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89484562022-03-25 Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers Huynen, Pascale Grégoire, Céline Gofflot, Stéphanie Seidel, Laurence Maes, Nathalie Vranken, Laura Delcour, Sandra Moutschen, Michel Hayette, Marie-Pierre Kolh, Philippe Melin, Pierrette Beguin, Yves Sci Rep Article Asymptomatic and pauci-symptomatic cases contribute to underestimating the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Moreover, we have few studies available on the longitudinal follow-up of SARS-CoV-2 antibodies after natural infection. We tested staff members of a Belgian tertiary academic hospital for SARS-CoV-2 IgG, IgM, and IgA antibodies. We analyzed the evolution of IgM and IgG after 6 weeks, and the persistence of IgG after 3 and 10 months. At the first evaluation, 409/3776 (10.8%) participants had a positive SARS-CoV-2 serology. Among initially seropositive participants who completed phases 2 and 3, IgM were still detected after 6 weeks in 53.1% and IgG persisted at 12 weeks in 82.0% (97.5% of those with more than borderline titers). IgG levels were higher and increased over time in symptomatic but were lower and stable in asymptomatic participants. After 10 months, 88.5% of participants had sustained IgG levels (97.0% of those with more than borderline titers). Nature Publishing Group UK 2022-03-25 /pmc/articles/PMC8948456/ /pubmed/35338237 http://dx.doi.org/10.1038/s41598-022-09215-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Huynen, Pascale
Grégoire, Céline
Gofflot, Stéphanie
Seidel, Laurence
Maes, Nathalie
Vranken, Laura
Delcour, Sandra
Moutschen, Michel
Hayette, Marie-Pierre
Kolh, Philippe
Melin, Pierrette
Beguin, Yves
Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title_full Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title_fullStr Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title_full_unstemmed Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title_short Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers
title_sort long-term longitudinal evaluation of the prevalence of sars-cov-2 antibodies in healthcare and university workers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948456/
https://www.ncbi.nlm.nih.gov/pubmed/35338237
http://dx.doi.org/10.1038/s41598-022-09215-8
work_keys_str_mv AT huynenpascale longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT gregoireceline longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT gofflotstephanie longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT seidellaurence longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT maesnathalie longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT vrankenlaura longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT delcoursandra longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT moutschenmichel longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT hayettemariepierre longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT kolhphilippe longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT melinpierrette longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers
AT beguinyves longtermlongitudinalevaluationoftheprevalenceofsarscov2antibodiesinhealthcareanduniversityworkers